Person

Oliver Zolk

Prof. Dr. med. Zolk
Title: Prof. Dr. med.
Denomination: Professor für Klinische Pharmakologie
Current position: Chefarzt Klinische Pharmakologie
Specialist qualification: Klinische Pharmakologie
Specialist field: Klinische Pharmakologie
Office address:
Campus Rüdersdorf
Seebad 82/83
15562 Rüdersdorf bei Berlin
Office phone number: +49 33638 83 991
Office email: oliver.zolk@mhb-fontane.de
 
At MHB since: 18.06.2020
Curriculum Vitae
Publications

Meine besten 5 Publikationen:

  1. Zolk O, Greiner T, Schneider M, Heinze M, Dahling V, Ramin T, Grohmann R, Bleich S, Zindler T, Toto S, Seifert J. Antipsychotic drug treatment of schizophrenia in later life: Results from the European cross-sectional AMSP study. World J Biol Psychiatry. 2021 Dec 15:1-13. doi: 10.1080/15622975.2021.2011403.

  2. Mannes M, Dopler A, Zolk O, Lang SJ, Halbgebauer R, Höchsmann B, Skerra A, Braun CK, Huber-Lang M, Schrezenmeier H, Schmidt CQ. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood. 2021 Jan 28;137(4):443-455. doi: 10.1182/blood.2020005959. PMID: 33507296.

  3. Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O; PanCareLIFE consortium. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. Eur J Cancer. 2020 Oct;138:212-224. doi: 10.1016/j.ejca.2020.07.019.

  4. Radtke S*, Zolk O*, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M,Schrappe M, Langer T. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013 Jun 27;121(26):5145-53. doi: 10.1182/blood-2013-01-480335. (*geteilte Erstautorenschaft)

  5. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.

 

Weitere/Alle Publikationen:

https://pubmed.ncbi.nlm.nih.gov/?term=zolk+o